{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T05:03:07Z","timestamp":1768194187606,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,29]]},"DOI":"10.7759\/cureus.83207","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T21:43:52Z","timestamp":1745963032000},"source":"Crossref","is-referenced-by-count":2,"title":["Ki-67 Levels and Their Association With Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Prospective Observational Study"],"prefix":"10.7759","author":[{"given":"Ramji Nalla","family":"Narendra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chellappa","family":"Vijayakumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gothati","family":"Haritha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahoo","family":"Ashok Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krishnamachari","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dubashi","family":"Biswajit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashok Badhe","family":"Bhawana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sundar","family":"Elangovan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.21.2492","article-title":"Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study","volume":"295","author":"Carey LA","year":"2006","unstructured":"Carey LA, Perou CM, Livasy CA, et al.. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006, 295:2492-502. 10.1001\/jama.295.21.2492","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.9284","article-title":"Breast cancer subtypes and the risk of local and regional relapse","volume":"28","author":"Voduc KD","year":"2010","unstructured":"Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010, 28:1684-91. 10.1200\/JCO.2009.24.9284","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn395","article-title":"Platinum-based chemotherapy in triple-negative breast cancer","volume":"19","author":"Sirohi B","year":"2008","unstructured":"Sirohi B, Arnedos M, Popat S, et al.. Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol. 2008, 19:1847-52. 10.1093\/annonc\/mdn395","journal-title":"Ann Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2834","article-title":"Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis","volume":"13","author":"Keam B","year":"2011","unstructured":"Keam B, Im SA, Lee KH, et al.. Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res. 2011, 13:R22. 10.1186\/bcr2834","journal-title":"Breast Cancer Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JGO.2016.005397","article-title":"Prevalence of triple-negative breast cancer in India: systematic review and meta-analysis","volume":"2","author":"Sandhu GS","year":"2016","unstructured":"Sandhu GS, Erqou S, Patterson H, Mathew A. Prevalence of triple-negative breast cancer in India: systematic review and meta-analysis. J Glob Oncol. 2016, 2:412-21. 10.1200\/JGO.2016.005397","journal-title":"J Glob Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer EA","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al.. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009, 45:228-47. 10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.4155","article-title":"Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival","volume":"24","author":"Cheang MC","year":"2006","unstructured":"Cheang MC, Treaba DO, Speers CH, et al.. Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol. 2006, 24:5637-44. 10.1200\/JCO.2005.05.4155","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp322","article-title":"Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009","volume":"20","author":"Goldhirsch A","year":"2009","unstructured":"Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Th\u00fcrlimann B, Senn HJ. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009, 20:1319-29. 10.1093\/annonc\/mdp322","journal-title":"Ann Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-486","article-title":"Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment","volume":"11","author":"Fasching PA","year":"2011","unstructured":"Fasching PA, Heusinger K, Haeberle L, et al.. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer. 2011, 11:486. 10.1186\/1471-2407-11-486","journal-title":"BMC Cancer"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djp390","article-title":"Re: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer","volume":"101","author":"Howell SJ","year":"2009","unstructured":"Howell SJ, Wardley AM, Armstrong AC. Re: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009, 101:1730; author reply 1730-1. 10.1093\/jnci\/djp390","journal-title":"J Natl Cancer Inst"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70262-1","article-title":"Ki67 in breast cancer: prognostic and predictive potential","volume":"11","author":"Yerushalmi R","year":"2010","unstructured":"Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010, 11:174-83. 10.1016\/S1470-2045(09)70262-1","journal-title":"Lancet Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22618","article-title":"Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry","volume":"109","author":"Bauer KR","year":"2007","unstructured":"Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer. 2007, 109:1721-8. 10.1002\/cncr.22618","journal-title":"Cancer"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1159\/000362756","article-title":"Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis of feasibility and rates of pathologic complete response","volume":"59","author":"Kern P","year":"2013","unstructured":"Kern P, Kalisch A, Kolberg HC, et al.. Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis of feasibility and rates of pathologic complete response. Chemotherapy. 2013, 59:387-94. 10.1159\/000362756","journal-title":"Chemotherapy"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s13193-012-0138-2","article-title":"Triple negative breast cancer - our experience and review","volume":"3","author":"Krishnamurthy S","year":"2012","unstructured":"Krishnamurthy S, Poornima R, Challa VR, Goud YG. Triple negative breast cancer - our experience and review. Indian J Surg Oncol. 2012, 3:12-6. 10.1007\/s13193-012-0138-2","journal-title":"Indian J Surg Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0162","article-title":"Efficacy of neoadjuvant carboplatin plus docetaxel in triple-negative breast cancer: combined analysis of two cohorts","volume":"23","author":"Sharma P","year":"2017","unstructured":"Sharma P, L\u00f3pez-Tarruella S, Garc\u00eda-Saenz JA, et al.. Efficacy of neoadjuvant carboplatin plus docetaxel in triple-negative breast cancer: combined analysis of two cohorts. Clin Cancer Res. 2017, 23:649-57. 10.1158\/1078-0432.CCR-16-0162","journal-title":"Clin Cancer Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/1746-1596-9-43","article-title":"Clinicopathologic features of triple negative breast cancers: an experience from Pakistan","volume":"9","author":"Hashmi AA","year":"2014","unstructured":"Hashmi AA, Edhi MM, Naqvi H, Faridi N, Khurshid A, Khan M. Clinicopathologic features of triple negative breast cancers: an experience from Pakistan. Diagn Pathol. 2014, 9:43. 10.1186\/1746-1596-9-43","journal-title":"Diagn Pathol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-7-203","article-title":"Prognostic impact of clinicopathologic parameters in stage II\/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer","volume":"7","author":"Keam B","year":"2007","unstructured":"Keam B, Im SA, Kim HJ, et al.. Prognostic impact of clinicopathologic parameters in stage II\/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. BMC Cancer. 2007, 7:203. 10.1186\/1471-2407-7-203","journal-title":"BMC Cancer"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3634","article-title":"Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer","volume":"16","author":"Singh J","year":"2014","unstructured":"Singh J, Novik Y, Stein S, et al.. Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer. Breast Cancer Res. 2014, 16:R32. 10.1186\/bcr3634","journal-title":"Breast Cancer Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.121","article-title":"Minichromosome maintenance protein 2 is a strong independent prognostic marker in breast cancer","volume":"21","author":"Gonzalez MA","year":"2003","unstructured":"Gonzalez MA, Pinder SE, Callagy G, et al.. Minichromosome maintenance protein 2 is a strong independent prognostic marker in breast cancer. J Clin Oncol. 2003, 21:4306-13. 10.1200\/JCO.2003.04.121","journal-title":"J Clin Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1309\/AJCP9DV3EVZUATFV","article-title":"Hormone receptor status rather than HER2 status is significantly associated with increased Ki-67 and p53 expression in triple-negative breast carcinomas, and high expression of Ki-67 but not p53 is significantly associated with axillary nodal metastasis in triple-negative and high-grade non-triple-negative breast carcinomas","volume":"135","author":"Han JS","year":"2011","unstructured":"Han JS, Cao D, Molberg KH, Sarode VR, Rao R, Sutton LM, Peng Y. Hormone receptor status rather than HER2 status is significantly associated with increased Ki-67 and p53 expression in triple-negative breast carcinomas, and high expression of Ki-67 but not p53 is significantly associated with axillary nodal metastasis in triple-negative and high-grade non-triple-negative breast carcinomas. Am J Clin Pathol. 2011, 135:230-7. 10.1309\/AJCP9DV3EVZUATFV","journal-title":"Am J Clin Pathol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1159\/000346475","article-title":"Correlation between Ki67 and breast cancer prognosis","volume":"84","author":"Kontzoglou K","year":"2013","unstructured":"Kontzoglou K, Palla V, Karaolanis G, et al.. Correlation between Ki67 and breast cancer prognosis. Oncology. 2013, 84:219-25. 10.1159\/000346475","journal-title":"Oncology"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600749","article-title":"Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome","volume":"88","author":"Faneyte IF","year":"2003","unstructured":"Faneyte IF, Schrama JG, Peterse JL, Remijnse PL, Rodenhuis S, van de Vijver MJ. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer. 2003, 88:406-12. 10.1038\/sj.bjc.6600749","journal-title":"Br J Cancer"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25309","article-title":"Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment","volume":"116","author":"Chang HR","year":"2010","unstructured":"Chang HR, Glaspy J, Allison MA, Kass FC, Elashoff R, Chung DU, Gornbein J. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment. Cancer. 2010, 116:4227-37. 10.1002\/cncr.25309","journal-title":"Cancer"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2012.12.004","article-title":"Final results from phase II trial of neoadjuvant docetaxel and capecitabine given sequentially or concurrently for HER2-negative breast cancers","volume":"13","author":"Zelnak AB","year":"2013","unstructured":"Zelnak AB, Styblo TM, Rizzo M, et al.. Final results from phase II trial of neoadjuvant docetaxel and capecitabine given sequentially or concurrently for HER2-negative breast cancers. Clin Breast Cancer. 2013, 13:173-9. 10.1016\/j.clbc.2012.12.004","journal-title":"Clin Breast Cancer"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn085","article-title":"Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial","volume":"100","author":"von Minckwitz G","year":"2008","unstructured":"von Minckwitz G, K\u00fcmmel S, Vogel P, et al.. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst. 2008, 100:542-51. 10.1093\/jnci\/djn085","journal-title":"J Natl Cancer Inst"},{"key":"ref26","article-title":"No increased Ki67 expression in ductal carcinoma in situ associated with invasive breast cancer","volume":"10","author":"Hoque A","year":"2001","unstructured":"Hoque A, Menter DG, Sahin AA, Sneige N, Lippman SM. No increased Ki67 expression in ductal carcinoma in situ associated with invasive breast cancer. Cancer Epidemiol Biomarkers Prev. 2001, 10:153-4.","journal-title":"Cancer Epidemiol Biomarkers Prev"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/25891-ki-67-levels-and-their-association-with-response-to-neoadjuvant-chemotherapy-in-triple-negative-breast-cancer-a-prospective-observational-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T21:43:53Z","timestamp":1745963033000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/25891-ki-67-levels-and-their-association-with-response-to-neoadjuvant-chemotherapy-in-triple-negative-breast-cancer-a-prospective-observational-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.83207","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,29]]}}}